Phase 2 Study of PIPE-791 in Idiopathic Pulmonary Fibrosis Initiated by Contineum Therapeutics
Contineum Therapeutics has initiated Phase 2 trial to assess PIPE-791 in patients with Idiopathic Pulmonary Fibrosis.
Asset / Drug
Drug and asset intelligence for PIPE-791 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.